Compounds > 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
Page last updated: 2024-10-21

1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one and ACD-MPV

1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one has been researched along with ACD-MPV in 1 studies

1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one: structure given in first source; inhibits guanylyl cyclase
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one : A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chester, M1
Seedorf, G1
Tourneux, P1
Gien, J1
Tseng, N1
Grover, T1
Wright, J1
Stasch, JP1
Abman, SH1

Other Studies

1 other study available for 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one and ACD-MPV

ArticleYear
Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
    American journal of physiology. Lung cellular and molecular physiology, 2011, Volume: 301, Issue:5

    Topics: Animals; Benzoates; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Female; Fetus; Guanylate Cy

2011